Teva launches Amorolfine medicated nail lacquer

Teva has announced the UK launch of its new Amorolfine five percent weight-for-volume medicated nail lacquer.

The new healthcare product is being made available immediately under the Teva 360 livery for a reduced initial price, in package sizes of 5ml.

It is a generic equivalent of Loceryl, an amorolfine hydrochloride-based medicated nail lacquer developed by Galderma, and is indicated for the treatment of onychomycoses caused by dermatophytes, yeasts and moulds without nail matrix involvement.

The original product from Galderma releases an active ingredient that can penetrate the nail to get to the infection site, while its once-to-twice-weekly application method offers ease of use.

Treatment processes for fungal nail infections – which would fail to clear up if left without intervention – can take between six and 12 months, in order to give the nails time to grow out.

It comes after Teva launched generic versions of Quetiapine, Desloratadine, Zolmitriptan and Naratriptan in recent days.